These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 28118483)

  • 1. Meta-Analysis of the Risk of Immune-Related Adverse Events With Anticytotoxic T-Lymphocyte-Associated Antigen 4 and Antiprogrammed Death 1 Therapies.
    Komaki Y; Komaki F; Yamada A; Micic D; Ido A; Sakuraba A
    Clin Pharmacol Ther; 2018 Feb; 103(2):318-331. PubMed ID: 28118483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Toxicity of immune checkpoints inhibitors].
    Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
    Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.
    Inno A; Metro G; Bironzo P; Grimaldi AM; Grego E; Di Nunno V; Picasso V; Massari F; Gori S
    Tumori; 2017 Sep; 103(5):405-421. PubMed ID: 28497847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitor-induced sarcoidosis-like granulomas.
    Rambhia PH; Reichert B; Scott JF; Feneran AN; Kazakov JA; Honda K; Koon H; Gerstenblith MR
    Int J Clin Oncol; 2019 Oct; 24(10):1171-1181. PubMed ID: 31321613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
    Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
    Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors.
    Hsiehchen D; Watters MK; Lu R; Xie Y; Gerber DE
    JAMA Netw Open; 2019 Sep; 2(9):e1911519. PubMed ID: 31532516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: A single-center experience.
    Kaur A; Doberstein T; Amberker RR; Garje R; Field EH; Singh N
    Medicine (Baltimore); 2019 Oct; 98(41):e17348. PubMed ID: 31593084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors.
    Kennedy LC; Bhatia S; Thompson JA; Grivas P
    J Natl Compr Canc Netw; 2019 Jun; 17(6):750-757. PubMed ID: 31200356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events associated with immune checkpoint inhibitor treatment for cancer.
    Esfahani K; Meti N; Miller WH; Hudson M
    CMAJ; 2019 Jan; 191(2):E40-E46. PubMed ID: 30642824
    [No Abstract]   [Full Text] [Related]  

  • 12. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.
    Mekki A; Dercle L; Lichtenstein P; Marabelle A; Michot JM; Lambotte O; Le Pavec J; De Martin E; Balleyguier C; Champiat S; Ammari S
    Eur J Cancer; 2018 Jun; 96():91-104. PubMed ID: 29698933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials.
    Costa R; Carneiro BA; Agulnik M; Rademaker AW; Pai SG; Villaflor VM; Cristofanilli M; Sosman JA; Giles FJ
    Oncotarget; 2017 Jan; 8(5):8910-8920. PubMed ID: 27852042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PD1/PDL1 induced psoriasis.
    Voudouri D; Nikolaou V; Laschos K; Charpidou A; Soupos N; Triantafyllopoulou I; Panoutsopoulou I; Aravantinos G; Syrigos K; Stratigos A
    Curr Probl Cancer; 2017; 41(6):407-412. PubMed ID: 29096940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.
    Nadeau BA; Fecher LA; Owens SR; Razumilava N
    Semin Liver Dis; 2018 Nov; 38(4):366-378. PubMed ID: 30357774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunotherapy is cancer treatment with a novel side-effect profile].
    Kondrup M; Raunkilde L; Svane IM; Schmidt H; Bastholt L
    Ugeskr Laeger; 2017 Oct; 179(40):. PubMed ID: 28992844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies: A Brief Communication.
    Michot JM; Ragou P; Carbonnel F; Champiat S; Voisin AL; Mateus C; Lambotte O; Annereau M
    J Immunother; 2018; 41(2):84-85. PubMed ID: 29252914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and Management of Immune Checkpoint Inhibitor-related Toxicities in Ovarian Cancer: A Series of Case Vignettes.
    Johnson C; Jazaeri AA
    Clin Ther; 2018 Mar; 40(3):389-394. PubMed ID: 29519715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment].
    Passat T; Touchefeu Y; Gervois N; Jarry A; Bossard C; Bennouna J
    Bull Cancer; 2018 Nov; 105(11):1033-1041. PubMed ID: 30244981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
    Boutros C; Tarhini A; Routier E; Lambotte O; Ladurie FL; Carbonnel F; Izzeddine H; Marabelle A; Champiat S; Berdelou A; Lanoy E; Texier M; Libenciuc C; Eggermont AM; Soria JC; Mateus C; Robert C
    Nat Rev Clin Oncol; 2016 Aug; 13(8):473-86. PubMed ID: 27141885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.